Silence Therapeutics makes a promotion

Tony Sedgwick becomes ceo

Silence Therapeutics, an RNA interference (RNAi) therapeutics company, has promoted Tony Sedgwick to chief executive from chief business officer.

The firm, which has operations in Berlin, Germany and London, UK has also announced the resignation of director Thomas Christely for personal reasons.

Sedgwick joined Silence in September 2011 to lead a new business development team and has been instrumental since then in helping shape the company's future strategy. He has extensive experience from European life science companies including more than 15 years at Roche. Prior to joining Silence, he was ceo of Novacta and chairman of Norwegian biotech Plastid.

You may also like

Regulatory

Silence strengthens US patent estate

Silence Therapeutics, developers of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced a further key US patent 9,695,423 has been granted to Silence this month
Research & Development

Silence Therapeutics to collaborate with Mirna

To evaluate delivery of new microRNA therapeutics
Research & Development

Silence Therapeutics and AstraZeneca extend siRNA deal

12-month extension to collaboration for the development of five siRNA programmes
Research & Development

A silent revolution

Increased understanding of RNA interference has led to an explosion of gene silencing drug research projects. Dr Sarah Houlton reviews the progress being made in recent drug trials and looks at the remaining challenges
Research & Development

Silence Therapeutics and Dainippon Sumitomo expand siRNA collaboration

Companies to examine delivery of RNAi therapeutics to additional disease targets
Research & Development

Agilent introduces the Altura Line of Inert HPLC Columns for superior results in biotherapeutic testing

Helping biopharma labs reach new heights in analytical performance
Regulatory

Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria

Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
Subscribe now